RAPID REDUCTION IN INVASIVE PNEUMOCOCCAL DISEASE (IPD) AFTER INTRODUCTION OF PCV7 TO THE NATIONAL IMMUNIZATION PLAN (NIP) IN ISRAEL
ESPID Education. Givon-Lavi N. Jun 7, 2011; 7711
Dr. Noga Givon-Lavi
Dr. Noga Givon-Lavi

This content is available to ESPID members only


Click here for more information or if you are considering becoming an ESPID member.

Abstract
Discussion Forum (0)
Rate & Comment (0)
Background and aims: PCV7 was licensed in Israel in 2007, with scattered use till 2009, and was introduced to the Israeli NIP in July 2009, as a 2, 4, 12m schedule, with catch-up (2 doses, 2nd year). IPD nationwide active surveillance has been conducted since 1989.
Methods: All 27 medical centers performing blood cultures in Israel participated by reporting monthly all IPD cases (defined by positive blood/CSF cultures). Capture-recapture methods were used to evaluate completeness. ~50% of isolates were submitted to serotyping until recent years, and >95% since 2000. Extrapolation by year, ethnic group, age, and serogroups was conducted to insure appropriate age-specific serotype-specific incidence assessment.
Results: During 1989-2010, 6,022 cases were reported. PCV7 serotypes+6A (VT) contributed ~50% of IPD. VT increased during 1989-2008, contributing to overall IPD increase. In 2004-8, mean IPD incidence/100,000 was 50 and 89 for <5 and <2 years, respectively. In 2010, VT incidence decreased by 80% and 85% compared with 2004-8 in <5 and <2 years respectively, (P<0.001). The respective overall IPD reduction was 41% and 45% with no replacement so far. In 2010, 72% of isolates causing remaining IPD <5 years were PCV13 serotypes.
Conclusions: PCV7 introduction to NIP as a 2+1 schedule with catch-up in <2 years, showed a rapid decrease in IPD <5 yrs. PCV7 was replaced by PCV13 since November 2010.
Code of conduct/disclaimer available in General Terms & Conditions

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies